Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2016, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 28, 44, 59, 12, 223, 50 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 12 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

3SBio Inc
4D Pharma Plc
A&G Pharmaceutical Inc
AB Science SA
AB2 Bio Ltd
AbbVie Inc
Ablynx NV
ACEA Biosciences Inc
Addex Therapeutics Ltd
Adello Biologics LLC
Advinus Therapeutics Ltd
AlphaMab Co Ltd
Alteogen Inc
Amgen Inc
Amura Holdings Ltd
Anacor Pharmaceuticals Inc
AnGes MG Inc
Applied Genetic Technologies Corp
Aptevo Therapeutics Inc
ARA Healthcare Pvt Ltd
Arena Pharmaceuticals Inc
arGEN-X BV
Arrien Pharmaceuticals LLC
Arthrogen BV
Asahi Kasei Pharma Corp
Asana BioSciences LLC
Astellas Pharma Inc
AstraZeneca Plc
Atlantic Bio Sci LLC
Aurigene Discovery Technologies Ltd
Avexxin AS
Axxam SpA
BCN Peptides SA
Beijing Hanmi Pharmaceutical Co Ltd
Bio-Cancer Treatment International Ltd
Biocad
Biocon Ltd
Biokine Therapeutics Ltd
BioLingus AG
BioLite Inc
Bionovis SA
BioTherapeutics Inc
Biozeus
Bird Rock Bio Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd
Cardax Inc
CASI Pharmaceuticals Inc
CEL-SCI Corp
Celgene Corp
Cellceutix Corp
Celldex Therapeutics Inc
Celltrion Inc
ChemoCentryx Inc
Chipscreen Biosciences Ltd
ChironWells GmbH
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Clevexel Pharma SA
CLL Pharma SA
Coherus BioSciences Inc
Commence Bio Inc
Compugen Ltd
Confluence Life Sciences Inc
CSL Ltd
Cyclacel Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Company Ltd
Diamyd Medical AB
Domainex Ltd
Dong-A Socio Holdings Co Ltd
Dr. Reddy's Laboratories Ltd
Eisai Co Ltd
Eli Lilly and Company
Enceladus Pharmaceuticals BV
Endocyte Inc
Enzene Biosciences Ltd
F. Hoffmann-La Roche Ltd
Fountain Biopharma Inc
Galapagos NV
Gene Techno Science Co Ltd
Genentech Inc
Genor BioPharma Co Ltd
Genosco Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Griffin Discoveries BV
Han Wha Pharma Co Ltd
Handok Inc
Hanmi Pharmaceuticals Co Ltd
Hansa Medical AB
Hanwha Chemical Corp
HEC Pharm Co Ltd
Hetero Drugs Ltd
HitGen LTD
Huabo Biopharm Co Ltd
Humabs BioMed SA
Hutchison MediPharma Ltd
Idera Pharmaceuticals Inc
Idogen AB
Iltoo Pharma
Immune Response BioPharma Inc
Immune Therapeutics Inc
Immungenetics AG
ImmunoFrontier Inc
Immupharma Plc
Innate Pharma SA
Innovent Biologics Inc
Intas Pharmaceuticals Ltd
Japan Tobacco Inc
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Jyant Technologies Inc
Kadmon Corp LLC
KAHR medical Ltd
Kang Stem Biotech Co Ltd
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
KPI Therapeutics Inc
Lead Pharma Holding BV
Lexicon Pharmaceuticals Inc
LG Life Science LTD
Lipocure Ltd
Livzon Pharmaceutical Group Inc
LSK BioPartners Inc
Lupin Ltd
Mabion SA
Mabtech Ltd
mAbxience SA
MacroGenics Inc
Mebiopharm Co Ltd
MedAnnex Ltd
Medestea Research & Production SpA
MediGene AG
MedImmune LLC
Merck KGaA
Mesoblast Ltd
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Modern Biosciences Plc
ModiQuest Group
Momenta Pharmaceuticals Inc
Morphotek Inc
Mycenax Biotech Inc
MYOS RENS Technology Inc
Myungmoon pharmaceutical Co Ltd
NanoSmart Pharmaceuticals Inc
Navigen Pharmaceuticals Inc
NeuClone Pty Ltd
Nissan Chemical Industries Ltd
Novartis AG
NovelMed Therapeutics Inc
NovImmune SA
Nuevolution AB
Omeros Corp
Oncobiologics Inc
Oncodesign SA
OncoImmune Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Oscotec Inc
OSE Immunotherapeutics
Panacea Biotec Ltd
Paras Biopharmaceuticals Finland Oy
Parvus Therapeutics Inc
Peptinov SAS
Pfenex Inc
Pfizer Inc
Pharmacyclics Inc
Pharmedartis GmbH
Philogen SpA
PLx Pharma Inc
Portola Pharmaceuticals Inc
Principia Biopharma Inc
Progenra Inc
ProNoxis AB
Protab Ltd
Protalex Inc
Protalix BioTherapeutics Inc
Qu Biologics Inc
R Pharm
Re-Pharm Ltd
ReceptoPharm Inc
RedHill Biopharma Ltd
Redx Pharma Plc
Regeneron Pharmaceuticals Inc
Reliance Life Sciences Pvt Ltd
Resverlogix Corp
ReveraGen BioPharma Inc
Rhizen Pharmaceuticals SA
Ribomic Inc
Richter Gedeon Nyrt
Saje Pharma LLC
Sandoz International GmbH
Sareum Holdings Plc
SBI Biotech Co Ltd
Selecta Biosciences Inc
Selvita SA
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Henlius Biotech Co Ltd
Shanghai Pharmaceutical Co Ltd
Spherium Biomed SL
Synovo GmbH
Syntrix Biosystems Inc
Takeda Pharmaceutical Company Ltd
TechnoPhage SA
Teijin Pharma Ltd
The International Biotechnology Center (IBC) Generium
TheraMAB LLC
Toleranzia AB
Tumorend LLC
TxCell SA
U.S. Stem Cell Inc
UCB SA
United BioPharma Inc
Vaccinex Inc
Valeant Pharmaceuticals International Inc
VentiRx Pharmaceuticals Inc
Vicore Pharma AB
viDA Therapeutics Inc
Vitae Pharmaceuticals Inc
Vitaeris Inc
Xbrane Biopharma AB
Xencor Inc
XL-protein GmbH
XTL Biopharmaceuticals Ltd
Yungjin Pharm Co Ltd
Yuyu Pharma Inc
Zenith Capital Corp
Zenyaku Kogyo Co Ltd
Zydus Cadila Healthcare Ltd